Lerodalcibep

莱达西贝普

Report date: 2025/12/16 20:00:07

Base Information

Drug NameLerodalcibep
Drug Alias NameLIB-003HST 101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[11] 
Global Approved IndicationsHypercholesterolemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/12/12
Country/TerritoryUnited StatesTurkeyNorway +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLib Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesHasten Biopharmaceutical Co LtdLIB Therapeutics IncHasten Biopharma Co Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[10] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A